These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9925654)

  • 1. Characterization of apolipoprotein E7 (Glu(244)-->Lys, Glu(245)--->Lys), a mutant apolipoprotein E associated with hyperlipidemia and atherosclerosis.
    Yamamura T; Dong LM; Yamamoto A
    J Lipid Res; 1999 Feb; 40(2):253-9. PubMed ID: 9925654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human apolipoprotein E7:lysine mutations in the carboxy-terminal domain are directly responsible for preferential binding to very low density lipoproteins.
    Dong J; Balestra ME; Newhouse YM; Weisgraber KH
    J Lipid Res; 2000 Nov; 41(11):1783-9. PubMed ID: 11060347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced binding activity of an apolipoprotein E mutant, APO E5, to LDL receptors on human fibroblasts.
    Dong LM; Yamamura T; Yamamoto A
    Biochem Biophys Res Commun; 1990 Apr; 168(2):409-14. PubMed ID: 2334412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3' (Arg136-->His): association with mild dyslipidemia and double pre-beta very low density lipoproteins.
    Minnich A; Weisgraber KH; Newhouse Y; Dong LM; Fortin LJ; Tremblay M; Davignon J
    J Lipid Res; 1995 Jan; 36(1):57-66. PubMed ID: 7706948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E5 (Glu212-->Lys): increased binding to cell surface proteoglycans but decreased uptake and lysosomal degradation in cultured fibroblasts.
    Feussner G; Scharnagl H; Scherbaum C; Acar J; Dobmeyer J; Lohrmann J; Wieland H; März W
    J Lipid Res; 1996 Aug; 37(8):1632-45. PubMed ID: 8864947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of human apolipoprotein E variant gene: apolipoprotein E7 (Glu244,245----Lys244,245).
    Maeda H; Nakamura H; Kobori S; Okada M; Mori H; Niki H; Ogura T; Hiraga S
    J Biochem; 1989 Jan; 105(1):51-4. PubMed ID: 2738044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
    van Dijk KW; van Vlijmen BJ; de Winther MP; van 't Hof B; van der Zee A; van der Boom H; Havekes LM; Hofker MH
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2945-51. PubMed ID: 10591674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.
    Ji ZS; Fazio S; Mahley RW
    J Biol Chem; 1994 May; 269(18):13421-8. PubMed ID: 8175773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E mediates binding of normal very low density lipoprotein to heparin but is not required for high affinity receptor binding.
    Fielding PE; Ishikawa Y; Fielding CJ
    J Biol Chem; 1989 Jul; 264(21):12462-6. PubMed ID: 2745454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis.
    Huang Y; Ji ZS; Brecht WJ; Rall SC; Taylor JM; Mahley RW
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2952-9. PubMed ID: 10591675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
    Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects.
    Cohn JS; Tremblay M; Amiot M; Bouthillier D; Roy M; Genest J; Davignon J
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):149-59. PubMed ID: 8548416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective VLDL metabolism and severe atherosclerosis in mice expressing human apolipoprotein E isoforms but lacking the LDL receptor.
    Knouff C; Briand O; Lestavel S; Clavey V; Altenburg M; Maeda N
    Biochim Biophys Acta; 2004 Aug; 1684(1-3):8-17. PubMed ID: 15450205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.
    Sehayek E; Eisenberg S
    J Biol Chem; 1991 Sep; 266(27):18259-67. PubMed ID: 1917954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum remnant lipoproteins in patients with apolipoprotein E7 (apo E Suita).
    Yanagi K; Yamashita S; Hiraoka H; Ishigami M; Kihara S; Hirano K; Sakai N; Nozaki S; Funahashi T; Kameda-Takemura K; Kubo M; Tokunaga K; Matsuzawa Y
    Atherosclerosis; 1997 May; 131(1):49-58. PubMed ID: 9180244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-step mechanism of binding of apolipoprotein E to heparin: implications for the kinetics of apolipoprotein E-heparan sulfate proteoglycan complex formation on cell surfaces.
    Futamura M; Dhanasekaran P; Handa T; Phillips MC; Lund-Katz S; Saito H
    J Biol Chem; 2005 Feb; 280(7):5414-22. PubMed ID: 15583000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia.
    Mann WA; Meyer N; Weber W; Meyer S; Greten H; Beisiegel U
    J Lipid Res; 1995 Mar; 36(3):517-25. PubMed ID: 7775863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Distribution of the apolipoprotein-E and -E-complexes in lipoproteins of human serum with the apolipoprotein-E4/E3 phenotype].
    Hidaka H; Tozuka M; Yamauchi K; Sugano M; Nakabayashi T; Katsuyama T
    Rinsho Byori; 1997 Dec; 45(12):1172-6. PubMed ID: 9437899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase.
    Takahashi S; Suzuki J; Kohno M; Oida K; Tamai T; Miyabo S; Yamamoto T; Nakai T
    J Biol Chem; 1995 Jun; 270(26):15747-54. PubMed ID: 7797576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice.
    Kypreos KE; Morani P; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2001 May; 40(20):6027-35. PubMed ID: 11352738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.